A Phase 2 interventional study of Niclosamide Oral Tablet and Placebo in Covid19, sponsored by Entero Therapeutics. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-21.
Sponsored by Entero Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a two-part, Phase 2, multicentre, randomized, double blind, 2-arm placebo-controlled study in adults with moderate COVID-19 with gastrointestinal signs and symptoms
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →Entero Therapeutics is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part 2 only: Patients with a primary diagnosis of COVID-19 with or without pneumonia who are not planned to be hospitalized.
Exclusion Criteria:
Drug: Niclosamide Oral Tablet
Drug: Placebo
Niclosamide tablets 400 mg 3 times daily for 14 days
Matching placebo tablets 3 times daily for 14 days
Mortality
All-cause mortality
Time frame: From Day 1 to 6 weeks
TEAE
Proportion of patients with Treatment Emergent Adverse Events (TEAE) leading to study drug discontinuation
Time frame: From Day 1 to 6 weeks
SAEs
Serious adverse event (SAE) coded by System Organ Class (SOC) and Preferred Term (PT), using the Medical Dictionary for Regulatory Activities (MedDRA)
Time frame: From Day 1 to end of study
Safety laboratory
Change in safety laboratory tests from baseline to 6 weeks, the number of subjects with values low, normal, and high compared to the normal ranges pretreatment versus post-treatment will be provided
Time frame: From Day 1 to 6 weeks
Blood pressure
Change in sitting systolic and diastolic blood pressure from baseline to 6 weeks summarized descriptively by visit and presented as shift tables
Time frame: From Day 1 to 6 weeks
fecal RNA virus clearance
time to fecal RNA virus clearance (rectal swab or stool sample) assessed by RT-qPCR in the niclosamide group, compared to the placebo group (Part 2 only)
Time frame: From Day 1 to 6 weeks
Body temperature
Change in body temperature from baseline to 6 weeks summarized descriptively by visit and presented as shift tables
Time frame: From Day 1 to 6 weeks
Heart rate
Change in heart rate from baseline to 6 weeks summarized descriptively by visit and presented as shift tables
Time frame: From Day 1 to 6 weeks
SaO2
Change in SaO2 from baseline to 6 weeks summarized descriptively by visit and presented as shift tables
Time frame: From Day 1 to 6 weeks
ECG
Change in ECG parameters including: 1. PR interval 2. RR interval 3. QRS interval 4 QT interval 5. HR interval 6. QtcF interval. All intervals summarized descriptively by visit from baseline to 6 weeks
Time frame: From Day 1 to 6 weeks
No study locations are listed for this record.
Ran from Jan 2022 to primary completion in Jan 2022, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Niclosamide
Entero Therapeutics